• 1
    R. Mechoulam. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostag. Leukotr. Ess. 2002, 66, 93.
  • 2
    R.G. Pertwee. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict. Biol. 2008, 13, 147.
  • 3
    R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, M.R. Elphick, P.J. Greasley, H.S. Hansen, G. Kunos, K. Mackie, R. Mechoulam, R.A. Ross. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol. Rev. 2010, 62, 588.
  • 4
    A.B. Lynn, M. Herkenham. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 1994, 268, 1612.
  • 5
    V. Vellani, S. Petrosino, L. De Petrocellis, M. Valenti, M. Prandini, P.C. Magherini, P.A. McNaughton, V. Di Marzo. Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. Neuropharmacology 2008, 55, 1274.
  • 6
    Y. Okamoto, K. Tsuboi, N. Ueda. Enzymatic formation of anandamide. Vitam. Horm. 2009, 81, 1.
  • 7
    B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, N.B. Gilula. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384, 83.
  • 8
    J.L. Blankman, G.M. Simon, B.F. Cravatt. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14, 1347.
  • 9
    L. De Petrocellis, M.G. Cascio, V. Di Marzo. The endocannabinoid system: a general view and latest additions. Brit. J. Pharmacol. 2004, 141, 765.
  • 10
    P. Pacher, S. Steffens. The emerging role of the endocannabinoid system in cardiovascular disease. Semin. Immunopathol.. 2009, 31, 63.
  • 11
    F.M. Di, L.A. Pini, G.P. Pelliccioli, P. Calabresi, P. Sarchielli. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. J. Neurol. Neurosur. Ps. 2008, 79, 1224.
  • 12
    L. Jean-Gilles, B. Gran, C.S. Constantinescu. Interaction between cytokines, cannabinoids and the nervous system. Immunobiology 2010, 215, 606.
  • 13
    I. Kaufmann, D. Hauer, V. Huge, M. Vogeser, P. Campolongo, A. Chouker, M. Thiel, G. Schelling. Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report. Eur. Surg. Res. 2009, 43, 325.
  • 14
    I. Kaufmann, G. Schelling, C. Eisner, H.P. Richter, T. Krauseneck, M. Vogeser, D. Hauer, P. Campolongo, A. Chouker, A. Beyer, M. Thie. Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology 2008, 33, 676.
  • 15
    J.P. Despres, A. Golay, L. Sjostrom. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl. J. Med. 2005, 353, 2121.
  • 16
    C. Grimaldi, A. Capasso. The endocannabinoid system in the cancer therapy: an overview. Curr. Med. Chem.. 2011, 18, 1575.
  • 17
    D. Hauer, P. Ratano, M. Morena, S. Scaccianoce, I. Briegel, M. Palmery, V. Cuomo, B. Roozendaal, G. Schelling, P. Campolongo. Propofol Enhances Memory Formation via an Interaction with the Endocannabinoid System. Anesthesiology 2011, 114, 1380.
  • 18
    M.N. Hill, G.E. Miller, E.J. Carrier, B.B. Gorzalka, C.J. Hillard. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009, 34, 1257.
  • 19
    E. Schwarz, P. Whitfield, S. Nahnsen, L. Wang, H. Major, F.M. Leweke, D. Koethe, P. Lio, S. Bahn. Alterations of primary fatty acid amides in serum of patients with severe mental illness. Front. Biosci.. 2011, 3, 308.
  • 20
    J.A. Lopez-Moreno, V. Echeverry-Alzate, K.M. Buhler. The genetic basis of the endocannabinoid system and drug addiction in humans. J. Psychopharmacol. 2012, 26, 133.
  • 21
    D. Economidou, L. Mattioli, M. Ubaldi, A. Lourdusamy, L. Soverchia, G. Hardiman, P. Campolongo, V. Cuomo, R. Ciccocioppo. Role of cannabinoidergic mechanisms in ethanol self-administration and ethanol seeking in rat adult offspring following perinatal exposure to Delta9-tetrahydrocannabinol. Toxicol. Appl. Pharm. 2007, 223, 73.
  • 22
    J.J. Burston, J.L. Wiley, A.A. Craig, D.E. Selley, L.J. Sim-Selley. Regional enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure. Brit. J. Pharmacol. 2010, 161, 103.
  • 23
    T. Rubino, D. Vigano, P. Massi, M. Spinello, E. Zagato, G. Giagnoni, D. Parolaro. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 2000, 39, 1331.
  • 24
    J. Villares. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 2007, 145, 323.
  • 25
    A.J. Budney, J.R. Hughes, B.A. Moore, R. Vandrey. Review of the validity and significance of cannabis withdrawal syndrome. Am. J. Psychiat. 2004, 161, 1967.
  • 26
    P. Campolongo, B. Roozendaal, V. Trezza, D. Hauer, G. Schelling, J.L. McGaugh, V. Cuomo. Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 4888.
  • 27
    M. Ranganathan, G. Braley, B. Pittman, T. Cooper, E. Perry, J. Krystal, D.C. D'Souza. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology (Berl) 2009, 203, 737.
  • 28
    A. Gash, J.S. Karliner, D. Janowsky, C.R. Lake. Effects of smoking marihuana on left ventricular performance and plasma norepinephrine: studies in normal men. Ann. Intern. Med. 1978, 89, 448.
  • 29
    A. Chouker, I. Kaufmann, S. Kreth, D. Hauer, M. Feuerecker, D. Thieme, M. Vogeser, M. Thiel, G. Schelling. Motion sickness, stress and the endocannabinoid system. PLoS One 2010, 5, e10752.
  • 30
    M. Naef, S. Russmann, S. Petersen-Felix, R. Brenneisen. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J. Pharm. Sci. 2004, 93, 1176.
  • 31
    L.K. Vaughn, G. Denning, K.L. Stuhr, H. de Wit, M.N. Hill, C.J. Hillard. Endocannabinoid signalling: has it got rhythm? Brit. J. Pharmacol. 2010, 160, 530.
  • 32
    M.G. Balvers, K.C. Verhoeckx, R.F. Witkamp. Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877, 1583.
  • 33
    F. Fanelli, V.D. Di Lallo, I. Belluomo, R. De Iasio, M. Baccini, E. Casadio, D. Ibarra Gasparini, M. Colavita, A. Gambineri, G. Grossi, V. Vicennati, R. Pasquali, U. Pagotto. Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimension-LC/MS/MS. J. Lipid Res.. 2011, 53, 481.
  • 34
    K. Sugamura, S. Sugiyama, T. Nozaki, Y. Matsuzawa, Y. Izumiya, K. Miyata, M. Nakayama, K. Kaikita, T. Obata, M. Takeya, H. Ogawa. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009, 119, 28.
  • 35
    M. Vogeser, D. Hauer, S. Christina Azad, E. Huber, M. Storr, G. Schelling. Release of anandamide from blood cells. Clin. Chem. Lab. Med. 2006, 44, 488.
  • 36
    R. Kuepper, P.D. Morrison, J. van Os, R.M. Murray, G. Kenis, C. Henquet. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr. Res. 2010, 121, 107.
  • 37
    O.D. Zhukov, M.V. Artamonov, V.M. Klimashevs'kyii, N.M. Hoseieva, V.M. Marhitych, N.M. Hula. [N-acylethanolamine–a new class of natural adrenotropic modulators]. Ukr. Biokhim. Zh.. 2000, 72, 24.
  • 38
    A. Dlugos, E. Childs, K.L. Stuhr, C.J. Hillard, H. de Wit. Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 2012, 37, 2416.
  • 39
    C. Strewe, M. Feuerecker, I. Nichiporuk, I. Kaufmann, D. Hauer, B. Morukov, G. Schelling, A. Chouker. Effects of parabolic flight and spaceflight on the endocannabinoid system in humans. Rev. Neurosci.. 2012, 0, 1.
  • 40
    A. Choukèr, I. Kaufmann, S. Kreth, D. Hauer, M. Feuerecker, D. Thieme, M. Vogeser, M. Thiel, G. Schelling. Motion sickness, stress and the endocannabinoid system. PLoS One 2010, 5, e10752.
  • 41
    M. Feuerecker, D. Hauer, M. Toth, F. Demetz, J. Hölzl, M. Thiel, I. Kaufmann, G. Schelling, A. Chouker. Effects of exercise stress on the endocannabinoid system in humans under field conditions. Eur. J. Appl. Physiol.. 2012, 112, 2777.
  • 42
    E. Heyman, F.X. Gamelin, M. Goekint, F. Piscitelli, B. Roelands, E. Leclair, V. Di Marzo, R. Meeusen. Intense exercise increases circulating endocannabinoid and BDNF levels in humans-Possible implications for reward and depression. R. Meeusen. Psychoneuroendocrinology 2011, 37, 844.
  • 43
    V. Di Marzo, F. Berrendero, T. Bisogno, S. Gonzalez, P. Cavaliere, J. Romero, M. Cebeira, J.A. Ramos, J.J. Fernandez-Ruiz. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J. Neurochem. 2000, 74, 1627.
  • 44
    C.J. Morgan, E. Page, C. Schaefer, K. Chatten, A. Manocha, S. Gulati, H.V. Curran, B. Brandner, F.M. Leweke. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Brit. J. Psychiat. 2013.
  • 45
    M. Feuerecker, D. Hauer, T. Gresset, S. Lassas, I. Kaufmann, M. Vogeser, J. Briegel, C. Hornuss, A. Chouker, G. Schelling. Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans. Alcohol Alcoholism 2012, 47, 226.
  • 46
    G. Schelling, D. Hauer, S.C. Azad, M. Schmoelz, A. Chouker, M. Schmidt, C. Hornuss, M. Rippberger, J. Briegel, M. Vogeser. Effects of general anesthesia on anandamide blood levels in humans. Anesthesiology 2006, 104, 273.
  • 47
    F. Weis, A. Beiras-Fernandez, D. Hauer, C. Hornuss, R. Sodian, S. Kreth, J. Briegel, G. Schelling. Effect of anaesthesia and cardiopulmonary bypass on blood endocannabinoid concentrations during cardiac surgery. Brit. J. Anaesth. 2010, 105, 139.
  • 48
    D. Hauer, G. Schelling, P. Campolongo, J. Morath, B. Roozendaal, G. Hamuni, A. Karabatsiakis, P. Atsak, M. Vogeser, K. I.T. Plasma concentrations of endocannabinoids and related primary Fatty Acid amides in patients with post-traumatic stress disorder. Plos One 2013, 8, e62741.
  • 49
    G.A. Fraser. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci. Ther. 2009, 15, 84.
  • 50
    J. Fiz, M. Duran, D. Capella, J. Carbonell, M. Farre. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One 2011, 6, e18440.
  • 51
    M. Karst, K. Salim, S. Burstein, I. Conrad, L. Hoy, U. Schneider. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003, 290, 1757.